



Please type a plus sign (+) inside this box. FORM PTO/SB08

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/541,633		
		Filing Date	06/30/2006		
		First Named Inventor	Oliver Planz et al.		
		Group Art Unit	1614		
		Confirmation No.	3490		
		Examiner Name	Leonard M. Williams		
Sheet	1	of	4	Attorney Docket Number	7003/42

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Issue Date MM-DD-YYYY
		Number	Class/Subclass		

Examiner Initials*	Cite No. ¹	U.S. Patent Applications		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Class/Subclass		

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office ³	Number			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	A.W. Kuss et al., "A1 expression is stimulated by CD40 in B cells and rescues WEHI 231 cells from anti-IgM-induced cell death," <i>Eur. J. Immunol.</i> , Vol. 29, (1999) pgs. 3077-3088.	
	2.	D.T. Dudley et al., "A Synthetic inhibitor of the mitogen-activated protein kinase cascade", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, August 1995, Pgs. 7686-7689.	
	3.	A. Denk et al., "Activation of NF- κ B via the I κ B Kinase Complex Is Both Essential and Sufficient for Proinflammatory Gene Expression in Primary Endothelial Cells", <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 30, July 27, 2001, Pgs. 28451-28458.	
	4.	R.T.C. Huang Ph.D. et al., "Anti-Influenza Viral Activity of Aspirin in Cell Culture", ©1998 by the Massachusetts Medical Society printed in the U.S.A.; Reprinted in <i>The New England Journal of Medicine</i> , Vol. 319: No. 797, September 22, 1988.	
	5.	K.A. Higgins et al., "Antisense inhibition of the p65 subunit of NF- κ B blocks tumorigenicity and causes tumor regression", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, November 1993, Pgs. 9901-9905.	
	6.	E.Y. Moon et al., "Benzylamide Sulindac Analogues Induce Changes in Cell Shape, Loss of Microtubules and G ₂ -M Arrest in a Chronic Lymphocytic Leukemia (CLL) Cell Line and Apoptosis in Primary CLL Cells", <i>Cancer Research</i> , Vol. 62, October 15, 2002, Pgs. 5711-5719.	

Examiner Signature	/Sahar Javanmard/	Date Considered	02/18/2008
--------------------	-------------------	-----------------	------------

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English Language Translation is attached.

References not provided

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/541,633
Filing Date	06/30/2006
First Named Inventor	Oliver Planz et al.
Group Art Unit	1614
Confirmation No.	3490
Examiner Name	Leonard M. Williams
Attorney Docket Number	7003/42

Sheet 2 of 4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
	7.	J.K. Lin et al., "Cancer Chemoprevention by Tea Polyphenols through Mitotic Signal Transduction Blockade", <i>Biochemical Pharmacology</i> , Vol. 58, (1999), Pgs. 911-915.	
	8.	R. Deshpande et al., "Estradiol Down-Regulates LPS-Induced Cytokine Production and NFkB Activation in Murine Macrophages", <i>American Journal of Reproductive Immunology</i> , ©1997 Munksgaard, Printed in the United States of America, Vol. 38, Pgs. 46-54.	
	9.	L.V. Gubareva et al., "Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus", <i>The Journal of Infectious Diseases</i> , Vol. 178, (1998), Pgs. 1257-62.	
	10.	C. Scholtissek et al., "Failure to obtain drug-resistant variants of influenza virus after treatment with inhibiting doses of 3-deazaadenosine and H7", <i>Archives of Virology</i> , Vol. 119, (1991), Pgs. 111-118.	
	11.	F. Grignani et al., "High-Efficiency Gene Transfer and Selection of Human Hematopoietic Progenitor Cell with a Hybrid EBV/Retroviral Vector Expressing the Green Fluorescence Protein", <i>Cancer Research</i> , Vol. 58, January 1, 1998, Pgs. 14-19.	
	12.	M.F. Favata et al., "Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 29, July 17, 1998, Pgs. 18623-18632.	
	13.	X. Wang et al., "Influenza A Virus NS1 Protein Prevents Activation of NF-kB and Induction of Alpha/Beta Interferon", <i>Journal of Virology</i> , Vol. 74, No. 24, December 2000, Pgs. 11566-11573.	
	14.	S. Ludwig et al., "Influenza Virus-induced AP-1-dependent Gene Expression Requires Activation of the JNK Signaling Pathway", <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 14, Issue of April 6, 2001, Pgs. 10990-10998.	
	15.	S. Pleschka et al., "Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade", <i>Nature Cell Biology</i> , Vol. 3, March 2001, Brief Communications: Pgs. 301-305; Supplementary Information: Pgs. 1-2.	
	16.	S. M. Plummer et al., "Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex", <i>Oncogene</i> , Vol. 18, (1999), Pgs. 6017-6020.	
	17.	W.M. Chu et al., "JNK2 and IKKβ Are Required for Activating the Innate Response to Viral Infection", <i>Immunity</i> , Vol. 11, December 1999, Pgs. 721-731.	

Examiner Signature	/Sahar Javanmard/	Date Considered	02/18/2008
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.† Unique citation designation number.‡ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).§ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.¶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.¶ Applicant is to place a check mark here if English Language Translation is attached.

References not provided

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	3	of	4	Complete if Known	Application Number	10/541,633
					Filing Date	06/30/2006
					First Named Inventor	Oliver Planz et al.
					Group Art Unit	1614
					Confirmation No.	3490
					Examiner Name	Leonard M. Williams
					Attorney Docket Number	7003/42

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	18.	U. K. Misra et al., "Ligation of the $\alpha_2\text{M}^*$ Signaling Receptor Regulates Synthesis of Cytosolic Phospholipase A ₂ ", <i>Archives of Biochemistry and Biophysics</i> , Vol. 386, No. 2, February 15, 2001, Pgs. 227-232.	
	19	O. Planz et al., "MEK-Specific Inhibitor U0126 Blocks Spread of Borna Disease Virus in Cultured Cells", <i>Journal of Virology</i> , Vol. 75, No. 10, May 2001, Pgs. 4871-4877.	
	20.	M.J. Robinson et al., "Mitogen-activated protein kinase pathways", <i>Current Opinion in Cell Biology</i> , Vol. 9, (1997), Pgs. 180-186.	
	21.	M. Zenichi, M.D., et al., "Molecular Mechanisms Involved in NSAID-induced Gastropathy", <i>Journal of Clinical Gastroenterology</i> , Vol. 27, Supplement 1, (1998), Pgs. S87-S90.	
	22.	J. Piette et al., "Multiple Redox Regulation in NF- κ B Transcription Factor Activation", <i>Biol. Chem.</i> , Vol. 378, November 1997, Pgs. 1237-1245.	
	23.	M. Karin et al., "NF- κ B In Cancer: From Innocent Bystander to Major Culprit", <i>Nature Reviews</i> , Vol. 2, April 2002, Pgs. 301-310.	
	24.	G. Liu et al., "NS-398 and Piroxicam Suppress UVB-induced Ap-1 Activity by Mechanism Independent of Cyclooxygenase-2", <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , November 13, 2002, Pgs. 1-22 and 9pgs. drawings.	
	25.	A. Jones, "Over-the-counter Analgesics: A Toxicologic Perspective", <i>American Journal of Therapeutics</i> , Vol. 9, (2002), Pgs. 245-257.	
	26.	D.R. Alessi et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase <i>In Vitro</i> and <i>In Vivo</i> ", <i>The Journal of Biological Chemistry</i> , Vol. 270, No. 46, Issue of November 17, 1995, Pgs. 27489-27494.	
	27.	S. Hattori et al., "Pentamethyl-Hydroxychromane, Vitamin E Derivative, Inhibits induction of Nitric Oxide Synthase By Bacterial Lipopolysaccharide", <i>Biochemistry and Molecular Biology International</i> , Vol. 37, No. 1, January 1995, Pgs. 177-183.	
	28.	J. Adams, "Proteasome inhibition: a novel approach to cancer therapy", <i>Trends in Molecular Medicine</i> , Vol. 8, No. 4 (Suppl.), (2002), Pgs. S49-S54.	
	29.	C. Tan et al., "Proteasome Inhibitor PS-341, a Potential Therapeutic Agent for Adult T-Cell Leukemia", <i>Cancer Research</i> , Vol. 62, February 15, 2002, Pgs. 1083-1086.	

Examiner Signature	/Sahar Javanmard/	Date Considered	02/18/2008
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English Language Translation is attached.

References not provided

Substitute for form 1449A/PTO				<i>Complete if Known</i> Application Number 10/541,633 Filing Date 06/30/2006 First Named Inventor Oliver Planz et al. Group Art Unit 1614 Confirmation No. 3490 Examiner Name Leonard M. Williams Attorney Docket Number 7003/42	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)					
Sheet	4	of	4		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
	30.	R. Treisman, "Regulation of transcription by MAP kinase cascades", <i>Current Opinion in Cell Biology</i> , Vol. 8 (1996), Pgs. 205-215.	
	31.	P.D. Zamora et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals", <i>Cell</i> , Vol. 101, March 31, 2000, Pgs. 29-33.	
	32.	M.J. May et al., "Selective Inhibition of NF-κB Activation by a Peptide That Blocks the Interaction of NEMO with the IκB Kinase Complex", <i>Science</i> , Vol. 289, September 1, 2000, Pgs. 1550-1554.	
	33.	K.S. Berman et al., "Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB", <i>Clinical Cancer Research</i> , Vol. 8, February 2002, Pgs. 354-360.	
	34.	Y. Yamamoto et al., "Sulindac Inhibits Activation of the NF-κB Pathway", <i>The Journal of Biological Chemistry</i> , Vol. 274, No. 38, September 17, 1999, Pgs. 27307-27314.	
	35.	C. K. Weber et al., "Suppression of NF-κB Activity by Sulfasalazine Is Mediated by Direct Inhibition of IκB Kinases α and β", <i>Gastroenterology</i> , Vol. 119, (2000), Pgs. 1209-1218.	
	36.	T. Tuschl et al., "Targeted mRNA degradation by double-stranded RNA in vitro", downloaded from www.genesdev.org on April 13, 2007.	
	37.	M.J. Yin et al., "The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β", <i>Nature</i> , Vol. 396, November 5, 1998, Pgs. 77-80.	
	38.	P. Cohen, "The search for physiological substrates of MAP and SAP kinases in mammalian cells", <i>trends in CELL BIOLOGY</i> , Vol. 7, September 1997, Pgs. 353-361.	

Examiner Signature	Sahar Javanmard/	Date Considered	02/18/2008
--------------------	------------------	-----------------	------------

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw lines through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number.² Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3).³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible.⁵ Applicant is to place a check mark here if English Language Translation is attached.

References not provided